How to Take Jaypirca® (pirtobrutinib)

Not an actual patient.

Jaypirca is a tablet, not an infusion, that may be taken at home or on the go to treat CLL or MCL

Take Jaypirca exactly as your healthcare provider tells you.

Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking Jaypirca if you develop side effects. Do not change your dose or stop taking Jaypirca without talking to your healthcare provider first.

Take Jaypirca 1 time each day, at about the same time each day.

Take Jaypirca with or without food. Swallow Jaypirca whole with water. Do not cut, crush, or chew the tablets.

If you miss a dose of Jaypirca, take it as soon as you remember on the same day. If it has been more than 12 hours, skip the missed dose and take your next dose on the next day at your usual time.

Understanding the possible side effects of Jaypirca for MCL and CLL

Jaypirca can cause serious side effects, including:

Infections
Bleeding problems (hemorrhage)
Decrease in blood counts (white blood cells, platelets, and red blood cells)
Heart rhythm problems (atrial fibrillation and atrial flutter)
Second primary cancers (new cancers including of the skin or other organs)
Liver problems

The most common side effects of Jaypirca include:

decreased white blood cell count
decreased red blood cell count
tiredness
decreased platelet count
decreased calcium

These are not all the possible side effects of Jaypirca. See Safety Summary below for more information.

If you experience side effects while on treatment, it’s important to talk to your doctor.

Stopping treatment due to side effects

83% of people with CLL kept taking Jaypirca without needing to stop treatment due to side effects.

In a clinical trial that compared Jaypirca with 2 other treatments:

17% of people with CLL (20 out of 116) stopped taking Jaypirca permanently due to side effects
Side effects that caused more than 1% of patients to permanently stop taking Jaypirca included pneumonia, COVID-19, COVID-19 pneumonia, low white blood cell count, and low red blood cell count

91% of people with MCL kept taking Jaypirca without needing to stop treatment due to side effects.

In a clinical trial:

9% of people with MCL (12 out of 128) stopped taking Jaypirca permanently due to side effects
Side effects that caused more than 1% of patients to permanently stop taking Jaypirca included pneumonia

SAFETY SUMMARY

Warnings - Jaypirca may cause serious side effects, including:

Infections. Infections can happen during treatment with Jaypirca. These infections can be serious and may lead to death. Your doctor may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your doctor right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with Jaypirca.

Bleeding problems (hemorrhage). Bleeding problems can happen during treatment with Jaypirca. They can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your doctor if you have any signs or symptoms of bleeding, including:

blood in your stools or black stools (looks like tar)
pink or brown urine
unexpected bleeding, or bleeding that is severe or you cannot control
vomit blood or vomit blood that looks like coffee grinds

cough up blood or blood clots
increased bruising
dizziness
weakness
confusion
changes in your speech
headache that lasts a long time

Decrease in blood cell counts. Decrease in white blood cells, platelets, and red blood cells are common with Jaypirca, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your doctor should do blood tests regularly during treatment to monitor your counts.

Heart rhythm problems. Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with Jaypirca. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your doctor if you have any of the following symptoms:

fast or irregular heartbeat (palpitations)
dizziness
fainting

chest discomfort
shortness of breath

Second primary cancers. New cancers have happened during treatment with Jaypirca, including cancers of the skin or other organs. Your doctor will check you for other cancers during treatment. Use sun protection when you are outside in sunlight.

Liver Problems. Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with Jaypirca. Your doctor will do blood tests to check your liver before and during treatment with Jaypirca. Tell your doctor or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

Your doctor may decrease your dose, temporarily stop, or permanently stop treatment with Jaypirca if you develop severe side effects.

Common side effects

decreased white blood cell count
decreased red blood cell count
tiredness

decreased platelet count
decreased calcium

These are not all the possible side effects with Jaypirca. Call your doctor for medical advice about side effects. You may report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before taking Jaypirca, tell your doctor about all your medical conditions, including if you:

have an infection or have been advised that you are at increased risk of infection
have had recent surgery or plan to have surgery. Your doctor may stop Jaypirca for a planned medical, surgical, or dental procedure
have bleeding problems and/or are taking blood thinner medicine
have or have had heart rhythm problems
have high blood pressure
have a history of other cancers, including skin cancer
have kidney problems
have liver problems
are pregnant or plan to become pregnant. Jaypirca can harm your unborn baby. If you are able to become pregnant, your doctor will do a pregnancy test before starting treatment
- Females who are able to become pregnant should use effective birth control (contraception) during treatment and for at least 1 week after the last dose of Jaypirca. Tell your doctor right away if you become pregnant or think you are pregnant during treatment
are breastfeeding or plan to breastfeed. It is not known if Jaypirca passes into breast milk. Do not breastfeed during treatment and for at least 1 week after your final dose

Also tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Jaypirca with certain other medicines may affect how Jaypirca or the other medicines work and can cause side effects.

How to take

Take Jaypirca exactly as your doctor tells you
Do not change your dose or stop taking Jaypirca unless your healthcare provider tells you to do so
Take Jaypirca 1 time each day at about the same time each day
Take Jaypirca with or without food
Swallow Jaypirca whole with water. Do not cut, crush, or chew the tablets
If you miss a dose of Jaypirca, take it as soon as you remember on the same day. If you miss taking a dose by more than 12 hours from the time you usually take Jaypirca, skip the missed dose. Take the next dose on the next day at your usual time

Learn more

Jaypirca is a prescription medicine. For more information, call 1-800-545-5979 or go to www.jaypirca.lilly.com. This summary provides basic information about Jaypirca but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Jaypirca and how to take it. Your doctor is the best person to help you decide if Jaypirca is right for you.

PT CON BS COMBO DEC2025

Jaypirca^® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

INDICATIONS

Jaypirca^® (JAY-PIHR-KAA) is a prescription medicine used to treat adults with:

mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment and who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.

Jaypirca was approved for this indication based on how many people responded to treatment. Studies are ongoing to confirm the benefit of Jaypirca for this use.

chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to previous treatment and who have already been treated with a BTK inhibitor for their cancer.

It is not known if Jaypirca is safe and effective in children.